文献速递消化道肿瘤与早癌消化内镜

结直肠癌筛查的参与率与使用便捷性:两种粪便免疫化学检测的比较

Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

在荷兰结直肠癌筛查项目中,配对队列研究比较两种粪便免疫化学检测(FIT)的使用便捷性,随机对照试验比较参与率与可分析性。FOB-Gold被认为显著但轻微更易使用,但两种FIT的参与率和可分析检测数无显著差异。

要点

  • 配对队列中50%受邀者完成两种FIT,98%返回问卷;FOB-Gold被认为显著更易使用。
  • 随机试验中FOB-Gold返回率48.7% vs OC-Sensor 48.9%,差值-0.2%(CI -3.4%至3.0%),在5%非劣效界值内(P=0.001)。
  • 不可分析检测FOB-Gold 1例(0.1%)vs OC-Sensor 4例(0.4%),P=0.18。

主要发现

  • 配对队列研究42,179名受邀者中,21,078名(50%)完成两种检测,20,727名(98%)返回问卷。
  • FOB-Gold被报告显著更易使用;更多参与者偏好FOB-Gold(36%)而非OC-Sensor(5%),但多数无偏好(59%;P < 0.001)。
  • 随机试验中,FOB-Gold返回936/1,923(48.7%),OC-Sensor返回940/1,923(48.9%),差值-0.2%(置信区间-3.4%至3.0%),在预设5%非劣效界值内(P = 0.001)。
  • 不可分析检测:FOB-Gold 1例(0.1%),OC-Sensor 4例(0.4%)(P = 0.18)。

关键数值与推荐

  • 配对队列研究样本量42,179名受邀者。
  • 随机试验每组1,923名受邀者,非劣效界值5%。
  • 参与率差值-0.2%(CI -3.4%至3.0%),P = 0.001。
  • 不可分析检测比例FOB-Gold 0.1% vs OC-Sensor 0.4%,P = 0.18。

临床怎么用

  • 原文结论认为两种FIT作为初筛检测时参与率和可分析检测数不受影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The impact of fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening on disease incidence and mortality is affected by participation, which might be influenced by ease of use of the FIT. We compared the participation rates and ease of use of 2 different FITs in a CRC screening program. METHODS: There were two study designs within the Dutch CRC screening program. In a paired cohort study, all invitees received 2 FITs (OC-Sensor, Eiken, Japan, and FOB-Gold, Sentinel, Italy) and were asked to sample both from the same stool. Ease of use of both FITs was evaluated by a questionnaire. In a randomized controlled trial, invitees were randomly allocated to receive one of the 2 FITs to compare participation and analyzability. RESULTS: Of 42,179 invitees in the paired cohort study, 21,078 (50%) completed 2 tests and 20,727 (98%) returned the questionnaire. FOB-Gold was reported significantly easier to use. More participants preferred FOB-Gold (36%) than OC-Sensor (5%), yet most had no preference (59%; P < 0.001). In the randomized trial, 936 of 1,923 invitees (48.7%) returned the FOB-Gold and 940 of 1,923 invitees (48.9%) returned the OC-Sensor, a difference of -0.2% (confidence interval, -3.4% to 3.0%), well within the pre-specified 5% noninferiority margin (P = 0.001). Only one FOB-Gold (0.1%) and 4 OC-Sensors (0.4%) were not analyzable (P = 0.18). CONCLUSIONS: Although FOB-Gold was significantly but marginally considered easier to use than OC-Sensor, the number of analyzable tests and the participation rates in organized CRC screening are not affected when either of the FITs is implemented as a primary screening test.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. de Klerk CM, Wieten E, van der Steen A, et al. Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests. Am J Gastroenterol. 2019. PMID: 30789417. doi:10.14309/ajg.0000000000000148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。